Custirsen shows no survival benefit in metastatic prostate cancer

Share :
Published: 10 Oct 2016
Views: 2827
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Prof Fizazi meets with ecancertv at ESMO 2016 to discuss the results of the AFFINITY trial of custirsen, a clusterin upstream inhibitor which had previous indications of improved clinical outcomes for castration resistant prostate cancer.

He describes the results from the AFFINITY trial as failing to reach significant difference in overall survival, and considers future paths for clusterin-targeted cancer therapy.

Prof Fizazi presented these results to the conference, and news coverage of this story is available here.